Shahmanesh M, Bolton C H, Feneley R C, Hartog M
Br Med J. 1973 Jun 2;2(5865):512-4. doi: 10.1136/bmj.2.5865.512.
Serum cholesterol and triglyceride levels were estimated and oral glucose tolerance tests performed on 16 patients with carcinoma of the prostate before treatment and while receiving stilboestrol in doses of 1 mg, 7.5 mg, and 15 mg daily and conjugated equine oestrogens (Premarin) 15 mg daily. Serum triglyceride levels were greater than 170 mg/100 ml in nearly all the patients while receiving Premarin or stilboestrol 7.5 mg and 15 mg daily. In six out of 10 patients who were given stilboestrol 1 mg daily the serum triglycerides remained within the normal range. No significant effects on serum cholesterol levels or glucose tolerance tests were observed with the various oestrogen regimens. The results support previous suggestions that a daily dose of 1 mg of stilboestrol should be regularly used in the treatment of carcinoma of the prostate.
对16例前列腺癌患者在治疗前以及接受每日1毫克、7.5毫克和15毫克己烯雌酚治疗时，以及每日接受15毫克结合马雌激素（倍美力）治疗时，测定血清胆固醇和甘油三酯水平，并进行口服葡萄糖耐量试验。几乎所有接受倍美力或每日7.5毫克和15毫克己烯雌酚治疗的患者血清甘油三酯水平均高于170毫克/100毫升。在每日服用1毫克己烯雌酚的10例患者中，有6例患者的血清甘油三酯仍在正常范围内。各种雌激素治疗方案对血清胆固醇水平或葡萄糖耐量试验均未观察到显著影响。这些结果支持了之前的建议，即每日1毫克己烯雌酚应常规用于前列腺癌的治疗。
